Scientists in Scotland have unveiled a groundbreaking wearable device that uses artificial intelligence to forecast epileptic seizures several minutes before they occur. The team from Glasgow Caledonian University says this 'unique' headset could revolutionise how the condition is managed, offering unprecedented advanced warnings.
How the AI Seizure Prediction System Works
The innovative headset analyses both brainwaves and heart function to detect the subtle electrical and physiological patterns that signal an impending seizure. The AI algorithm, trained on thousands of hours of historical electroencephalography (EEG) and electrocardiography (ECG) data, can then issue a timely alert to the wearer.
The system boasts an accuracy of up to 95% and can even display its confidence level regarding the likelihood of a seizure. This crucial window allows individuals to take safety precautions, move to a secure location, or alert those around them.
A Potential Lifeline for Hundreds of Thousands
Professor Hadi Larijani, who leads the research team, emphasised the transformative potential. "Providing even a few minutes’ warning could be life changing," he stated. "Our goal is to empower patients and families with time to act to stay safe and live more independently."
Currently, no readily available device offers such predictive capability for epilepsy. The greatest benefit, according to Prof Larijani, may be the confidence it restores, helping to prevent secondary injuries caused by sudden seizures. This development is significant for the hundreds of thousands of people living with epilepsy in the UK and millions globally.
The Road to a Commercial Product
The research team used a custom-made "phantom head" with electrodes to simulate a real user during development. While initial prototypes relied on third-party hardware, the goal is to create a discrete, wireless, and lightweight final design—potentially resembling a cap—that is also suitable for children to wear.
The project has recently secured fresh support from UK Research and Innovation through its £9 million Proof of Concept programme. However, Professor Larijani notes that bringing a medical device to market involves navigating strict regulatory hurdles. "It takes time to get through the hurdles," he said, indicating widespread availability is still some years away, but confirming the team is now working on a "more commercial-ready product."
For the families affected, the promise is profound. "Even a brief warning means they can prevent injuries and reduce fear," Prof Larijani added. "That is the true measure of success for us."
